By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Intercept Pharmaceuticals 

450 W 15th Street
Suite 505
New York City  New York  10011  U.S.A.
Phone: 646-747-1000 Fax: 646-747-1001


SEARCH JOBS


Industry
Pharmaceutical






Company News
Intercept Pharma (ICPT) Reports Second Quarter 2017 Financial Results And Provides Business Update 7/31/2017 1:21:42 PM
Intercept Pharma (ICPT) Release: CONTROL Trial Shows Statin Therapy Reversed LDL Increases To Below Baseline Levels In NASH Patients Treated With OCA 7/31/2017 11:38:08 AM
Intercept Pharma (ICPT) Announces Positive Results From The Phase II AESOP Trial Evaluating OCA For The Treatment Of Patients With Primary Sclerosing Cholangitis 7/31/2017 11:36:04 AM
Intercept Pharma (ICPT) To Report Second Quarter 2017 Financial Results On July 31 7/26/2017 9:55:29 AM
Intercept Pharma (ICPT) Announces New Data Analysis From FLINT Trial Of OCA In NASH Patients With Type 2 Diabetes 6/12/2017 12:03:19 PM
Intercept Pharma (ICPT) Release: Health Canada Grants Approval For Ocaliva (Obeticholic Acid) For The Treatment Of Patients With Primary Biliary Cholangitis (PBC) 5/26/2017 10:43:40 AM
Intercept Pharma (ICPT) Reports First Quarter 2017 Financial Results And Provides Business Update 5/4/2017 11:12:31 AM
Intercept Pharma (ICPT) To Report First Quarter 2017 Financial Results On May 4 And Present At Upcoming Conference 4/28/2017 8:02:44 AM
Intercept Pharma (ICPT) Release: NICE Recommends Ocaliva┬« (Obeticholic Acid) For The Treatment Of Patients With Primary Biliary Cholangitis In England, Wales And Northern Ireland 3/2/2017 9:08:50 AM
Intercept Pharma (ICPT) Reports Full Year 2016 Financial Results And Provides Business Update 2/23/2017 11:14:22 AM
12345678910...
//-->